期刊文献+

三联疗法治疗十二指肠溃疡的临床观察 被引量:8

Clinical Effect of Gatifloxacin Based Triple Therapy in Treatment of Duodenal Ulcer
原文传递
导出
摘要 目的探讨加替沙星、泮托拉唑和阿莫西林一周疗法对幽门螺杆菌(Hp)阳性十二指肠溃疡治疗效果。方法将82例Hp阳性的十二指肠溃疡患者随机分为治疗组和对照组,分别使用加替沙星联合泮托拉唑、阿莫西林和泮托拉唑联合克拉霉素、阿莫西林进行治疗。结果治疗组、对照组的Hp根除率、溃疡愈合率、不良反应相比,差异均无统计学意义(P>0.05)。结论加替沙星、阿莫西林、泮托拉唑三联疗法对治疗Hp感染的十二指肠溃疡有较好的疗效。 Objective To explore the curative effect of seven days therapy consisted of gatifloxacin, amoxicillin and panto- prazote for H. Pylori positive duodenal ulcer. Methods Eighty two cases with Hp positive duodenal ulcer were randomly divided into two groups. The treatment group( n = 42) was treated with Gatifloxacin, amoxicillin and pantoprazole for seven days, while the control group( n = 40) was treated with elarithromycin, pantoprazole and amoxicillin for seven days. Results The eradication rate of Hp,rate of ulcer cicatrization and adverse events were similar in both groups(P 〉 0.05). Conclusion Gatifloxacin based triple therapy is safe and effective for H. Pylori positive duodenal ulcer.
出处 《中华全科医学》 2009年第7期720-721,共2页 Chinese Journal of General Practice
关键词 加替沙星 三联疗法 幽门螺杆菌 十二指肠溃疡 Gatifloxacin Triple therapy Helicobacter pylori Duodenal Ulcer
  • 相关文献

参考文献10

  • 1Gisbert JP, De LA, Morena F. Systematic and meta-analysis : levofloxacin-based rescue regimens after Helieobacter pylori treatment failure [ J ]. Alimentary Pharmacology & Therapeutics,2006,1 ( 23 ) :35.
  • 2Cammarota G, Ciancir, Cannizzaro O, et al. High-dose versus low-dose clarithromyein in 1-week triple therapy, including rabeprazole and levefloxaein, for Helicobaeter pylori eradication [ J ]. J Clin Gastroentero,2004,38 (2) :110-114.
  • 3成虹,胡伏莲,谢勇,胡品津,王吉耀,吕农华,张建中,张桂英,周曾芬,吴克利,张玲霞,彭孝伟,戴宁,唐国都,姜葵,李岩,侯晓华,白文元,王明春,叶红军,刘玉兰,许乐.中国幽门螺杆菌耐药状况以及耐药对治疗的影响—全国多中心临床研究[J].胃肠病学,2007,12(9):525-530. 被引量:518
  • 4Di Caro S, Zocco MA, Cremonini Ir, et al. Levofloxacin based regiments for the eradication of Helicobacter pylori [ J ]. European Journal of Gastroenterology&Hepatology ,2002,14 ( 12 ) : 1309.
  • 5Perri F, Festa V, Merla A, et al: Randomized study of differents second line therapies for helicobacter pylori infection after failure of the standard maastricht triple therapy [ J]. Aliment Pharmacol Ther,2003,18 (8) :815-820.
  • 6桑建忠.左氧氟沙星对治疗幽门螺旋杆菌的初步探讨[J].实用全科医学,2008,6(5):503-503. 被引量:8
  • 7Dennis M, Grasel S. Clinical pharmacology of gatifloxacin, a new fluoroquinolone [ J]. Clinical Infect Dis,2000,31 ( Suppl2 ) :S51-S58.
  • 8钟英强,许哲,夏忠胜,陈其奎,曾志勇,黄志清.以加替沙星为基础的三联疗法根除幽门螺杆菌感染的疗效和费用分析[J].中国新药与临床杂志,2005,24(5):394-397. 被引量:19
  • 9林楚卿,刘满芬,赖怀远.以加替沙星为基础的三联疗法根除幽门螺杆菌的疗效观察[J].河北医学,2008,14(1):47-49. 被引量:4
  • 10Zech K, Steinijans VW, Huber R,et al. Pharmacokinetics and drug interactions relevant ractors factor for the choice of a drug[ J]. Int J Clin Pharmacol, 1996,34( 1 ) :3.

二级参考文献25

  • 1钟英强,许哲,夏忠胜,陈其奎,曾志勇,黄志清.以加替沙星为基础的三联疗法根除幽门螺杆菌感染的疗效和费用分析[J].中国新药与临床杂志,2005,24(5):394-397. 被引量:19
  • 2成虹,胡伏莲.北京地区幽门螺杆菌耐药情况及其变化趋势[J].中华医学杂志,2005,85(39):2754-2757. 被引量:176
  • 3Saad RJ,Schoenfeld P,Kim HM.左氧氟沙星三联疗法治疗顽固性Hp感染优于铋剂四联疗法[J].中国处方药,2006,5(5):42-42. 被引量:40
  • 4成虹,胡伏莲,李江.幽门螺杆菌耐药性对其根除治疗影响的研究[J].中华医学杂志,2006,86(38):2679-2682. 被引量:97
  • 5CAMMAROTA G, CIANCI R, CANNIZZARO O, et al. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levefloxacin, for Helicobacter pylorieradication [J].J Clin Gastroenterol, 2004,38 (2): 110-114.
  • 6BOSQUES-PADILLA FJ, GARZA-GONZALEZ E, CALDERONLOZANO IE, et al. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication:7 vs 14 day treatment [J]. Helicobacter, 2004,9(5) :417-421.
  • 7FISH DN, NORTH DS. Gatifloxacin, an advanced 8-methory fluoroquinolone [J]. Pharmacotherapy, 2001,21 (1) :35-59.
  • 8SARAVOLATZ LD, LEGGETT J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolone [J]. Clin Infect Dis, 2003,37(9) :1210-1215.
  • 9KHURANA A, VINAYEK N, RECCO RA, et al. The incidence of clostridium diffile-associated and non-C. diffile-associated doarrhea after use of gatifloxacin and levofloxacin in an acute-care facility [J]. Clin Infect Dis, 2004,39(4) :602-603.
  • 10GRASELA DM, CHRISTOFALO B, KOLLIA GD, et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment [J]. Pharmacotherapy,2000,20 (6Pt2) :87S-94S.

共引文献541

同被引文献88

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部